Fab region-binding peptide

Patent metadata

Field	Value
Publication number	US-10556944-B2
Application number	US-201414914439-A
Country	US
Kind code	B2
Filing date	Aug 28, 2014
Priority date	Aug 30, 2013
Publication date	Feb 11, 2020
Grant date	Feb 11, 2020

Abstract

An object of the present invention is to provide a Fab region-binding peptide having an excellent ability for binding to a Fab region of IgG, an affinity separation matrix having the peptide as a ligand, and a method for producing a Fab region-containing protein, the method using the affinity separation matrix. Further, another object of the present invention is to provide a DNA encoding for the peptide, a vector containing the DNA, and a transformant which has been transformed by the vector. The Fab region-binding peptide according to the present invention is characterized in having a mutation at a specific site in comparison with wild-type SpG-β1.

First claim

The invention claimed is:

1. A Fab region-binding peptide represented by any one of the following (1) to (3):
(1) a Fab region-binding peptide having an amino acid sequence of SEQ ID NO: 1 derived from the β1 domain of protein G with substitution of an amino acid residue at not less than one position selected from the 13th, 19th, 30th and 33rd positions, and having a higher binding force to the Fab region of immunoglobulin than that before introduction of the substitution,
wherein the amino acid residue at the 13th position is substituted by Thr or Ser,
the amino acid residue at the 30th position is substituted by Val, Leu or Ile,
the amino acid residue at the 19th position is substituted by Val, Leu or Ile,
the amino acid residue at the 33rd position is substituted by Phe;

(2) a Fab region-binding peptide having an amino acid sequence specified in the (1) with deletion, substitution and/or addition of not less than 1 and not more than 7 amino acid residues at a region other than the 13th, 19th, 30th and 33rd positions, and having a higher binding force to the Fab region of immunoglobulin than the peptide having the amino acid sequence of SEQ ID NO: 1;
wherein the position of deletion, substitution and/or addition of an amino acid residue is at least one position selected from the group consisting of the 2nd, 10th, 15th, 18th, 21st, 22nd, 23rd, 24th, 25th, 27th, 28th, 31st, 32nd, 35th, 36th, 39th, 40th, 42nd, 45th, 47th, 48th and 50th positions;
the amino acid residue at the 2nd position is substituted by Arg,
the amino acid residue at the 10th position is substituted by Arg,
the amino acid residue at the 15th position is substituted by Gln or Thr,
the amino acid residue at the 18th position is substituted by Ala,
the amino acid residue at the 21st position is substituted by Ile, Ala or Asp
the amino acid residue at the 22nd position is substituted by Asn or Glu,
the amino acid residue at the 23rd position is substituted by Thr or Asp,
the amino acid residue at the 24th position is substituted by Thr,
the amino acid residue at the 25th position is substituted by Ser or Met,
the amino acid residue at the 27th position is substituted by Asp or Gly,
the amino acid residue at the 28th position is substituted by Arg, Asn or Ile,
the amino acid residue at the 31st position is substituted by Arg,
the amino acid residue at the 32nd position is substituted by Arg,
the amino acid residue at the 35th position is substituted by Phe or Tyr,
the amino acid residue at the 36th position is substituted by Gly,
the amino acid residue at the 39th position is substituted by Leu or Ile,
the amino acid residue at the 40th position is substituted by Val or Glu,
the amino acid residue at the 42nd position is substituted by Leu, Val or Gln,
the amino acid residue at the 45th position is substituted by Phe,
the amino acid residue at the 47th position is substituted by His, Asn, Ala, Gly or Tyr,
the amino acid residue at the 48th position is substituted by Thr, and
the amino acid residue at the 50th position is substituted by Arg or Glu,

(3) a Fab region-binding peptide having an amino acid sequence having not less than 85% sequence identity to the amino acid sequence specified in the (1), and having a higher binding force to the Fab region of immunoglobulin than the peptide having the amino acid sequence of SEQ ID NO: 1, wherein the substituted amino acid residue at not less than 1 position selected from the 13th, 19th, 30th, and 33rd positions of the amino acid sequence specified in the (1) is not further mutated in the (3).

2. The Fab region-binding peptide according to claim 1 , wherein the position of deletion, substitution and/or addition of an amino acid residue is at least one position selected from the 2nd, 10th, 15th, 18th, 21st, 22nd, 23rd, 24th, 25th, 27th, 28th, 31st, 32nd, 35th, 36th, 39th, 40th, 42nd, 45th, 47th and 48th positions of the amino acid sequence specified in the (2).

3. The Fab region-binding peptide according to claim 1 , wherein the position of deletion, substitution and/or addition of an amino acid residue is an N-terminus and/or a C-terminus of the amino acid sequence specified in the (2).

4. The Fab region-binding peptide according to claim 1 , wherein the sequence identity to the amino acid sequence specified in the (3) is not less than 95%.

5. A Fab region-binding peptide multimer, having not less than 2 domains wherein not less than 2 Fab region-binding peptides according to claim 1 are connected with one another.

6. An affinity separation matrix, wherein a Fab region-binding peptide according to claim 1 or a Fab region-binding peptide multimer according to claim 5 is immobilized on a water-insoluble carrier as a ligand.

7. A method for producing a Fab region-containing protein, comprising the steps of
contacting the affinity separation matrix according to claim 6 with a liquid sample containing the Fab region-containing protein, and
separating the Fab region-containing protein bound to the affinity separation matrix from the affinity separation matrix.

8. The Fab region-binding peptide according to claim 1 , wherein the sequence identity to the amino acid sequence specified in the (3) is not less than 90%.

Assignees

• Kaneka Corp

Inventors

• Yoshida Shinichi
• Murata Dai

Classifications

• C07K16/1275 Primary

  Streptococcus (G) · CPC title

• C07K14/315

  from Streptococcus (G), e.g. Enterococci · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/22 Primary

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• C07K2317/55

  Fab or Fab' · CPC title